KROS
Keros Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$221.47M
P/E Ratio
—
EPS
$-2.53
Beta
0.95
52W High
$22.55
52W Low
$9.79
50-Day MA
$11.37
200-Day MA
$15.33
Dividend Yield
—
Profit Margin
-256.60%
Forward P/E
15.65
PEG Ratio
—
About Keros Therapeutics Inc
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with a great unmet medical need. The company is headquartered in Lexington, Massachusetts.
Fundamentals
| Revenue (TTM) | $33.18M |
| Gross Profit (TTM) | $-61.35M |
| EBITDA | $-105.78M |
| Operating Margin | -7051.00% |
| Return on Equity | -16.80% |
| Return on Assets | -12.20% |
| Revenue/Share (TTM) | $1.04 |
| Book Value | $14.47 |
| Price-to-Book | 0.78 |
| Price-to-Sales (TTM) | 6.67 |
| EV/Revenue | 6490.26 |
| EV/EBITDA | -13.05 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -99.80% |
| Shares Outstanding | $19.79M |
| Float | $17.83M |
| % Insiders | 3.65% |
| % Institutions | 96.04% |
Historical Volatility
HV 10-Day
81.22%
HV 20-Day
63.71%
HV 30-Day
53.79%
HV 60-Day
62.89%
HV Rank
79.8%
Volatility is currently expanding
Analyst Ratings
Consensus ($21.83 target)
5
Buy4
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026